Psychiatric care in parkinson's disease

Journal of Psychiatric Practice

Volumn 19, Issue 2, 2013, Pages 118-141

  Quelhas, Rosa ^a  

^a Hospital de Pedro Hispano   (Portugal)

Author keywords

Anxiety; Depression; Insomnia; Parkinson's disease; Psychosis

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; BENZODIAZEPINE; CITALOPRAM; CLOZAPINE; DESIPRAMINE; DIAZEPAM; DULOXETINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LEVODOPA; LORAZEPAM; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE; SERTRALINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZIPRASIDONE; ZOLPIDEM;

ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; COGNITIVE THERAPY; CONFUSION; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; LONG TERM CARE; MENTAL HEALTH CARE; META ANALYSIS; MOTOR PERFORMANCE; MUSIC THERAPY; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PSYCHOEDUCATION; PSYCHOSIS; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAXATION TRAINING; REVIEW; SEROTONIN SYNDROME; SLEEP DISORDER; SYMPTOM ASSESSMENT; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; VISUAL HALLUCINATION;

ANTIPARKINSON AGENTS; ANXIETY; DEPRESSION; DISEASE MANAGEMENT; DRUG DOSAGE CALCULATIONS; HUMANS; MUSIC THERAPY; PARKINSON DISEASE; PATIENT EDUCATION AS TOPIC; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 84878103375     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000428558.94329.6d     Document Type: Review

References (240)

1. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Dis 2008;23:183-9.
2. Pincus JH, Tucker GJ. Movement, mood, and obsessive compulsion disorders. In: Pincus JH, Tucker GJ. Beha - vioral Neurology, 4th ed. New York: Oxford University Press; 2002:177-95.
3. Pontone GM, Williams JR, Anderson KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord 2009;24:1333-8.
4. Richard IH. Anxiety disorders in Parkinson's disease. Adv Neurol 2005;96:42-55.
5. Menza MA, Robertson-Hoffman DE, Banapace AS. Parkinson's disease and anxiety: Comorbidity with depression. Biol Psychiatry 1993;34:465-70.
6. Leentjens AF, Dujardin J, Marsh L, et al. Anxiety rating scales in Parkinson's disease: A validation study of the Hamilton Anxiety Rating Scale, the Beck Anxiety Inventory, and the Hospital Anxiety and Depression Scale. Mov Disord 2011;26:407-15.
7. Carson AJ, Zeman A, Myles L, et al. Neurology and neurosurgery. In: Levenson JL, ed. American Psychiatric Publishing textbook of psychosomatic medicine. Washington, DC: American Psychiatric Publishing; 2005:701-32.
8. Zarow C, Lyness SA, Mortimer JA, et al. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003;60:337-41.
9. Tohgi H, Abe T, Takahashi S, et al. Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms. Neurosci Lett 1993;150:71-4.
10. Raisman R, Cash R, Agid Y. Parkinson's disease: Decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology 1986;36:556-60.
11. D'Amato RJ, Zweig RM, Whitehouse PJ, et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987;22:229-36.
12. Iacono RP, Kuniyoshi SM, Ahlman JR, et al. Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkin - son's patients with severe postural instability and gait disorders. J Neural Transm 1997;104:451-9.
13. Winter C, von Rumohr A, Mundt A, et al. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 2007;184: 133-41.
14. Morón JA, Brockington A, Wise RA, et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines. J Neurosci 2002; 22:389-95.
15. Remy P, Doder M, Lees A, et al. Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005;128:1314-22.
16. Scholtissen B, Verley FRJ, Steinbush HWM, et al. Serotonergic mechanisms in Parkinson's disease: Opposing results from preclinical and clinical data. J Neural Transm 2006;113:59-73.
17. Pålhagen SE, Carlsson M, Curman E, et al. Depressive illness in Parkinson's disease-Indication of a more advanced and widespread neurodegenerative process? Acta Neurol Scand 2008;117:295-304.
18. Pålhagen SE, Ekberg S, Wålinder J, et al. HMPAO SPECT in Parkinson's disease (PD) with major depression (MD) before and after antidepressant treatment. J Neurol Vol 2009;256:1510-8.
19. Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life. Mov Disord 2006;21:1119-22.
20. Marsh L. Psychosis in Parkinson's disease. Curr Treat Options Neurol 2004;6:181-9.
21. Fernandez HH. Taking a closer look at sleep problems and psychosis in Parkinson's disease. Introduction. CNS Spectr 2008;13:4-5.
22. Scaravelli T, Gasparoli E, Rinaldi F, et al. Health related quality of life and sleep disorders in Parkinson's disease. Neurol Sciences 2003;24:209-10.
23. Wetter TC, Collado-Seidel V, Pollmacher T, et al. Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 2000;23:361-7.
24. Gagnon JF, Bedard MA, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59:585-9.
25. Ondo WG, Dat Vuong K, Buong K, et al. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001;57:1392-6.
26. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: A community-based study. Mov Disord 1999;14:922-7.
27. Homann CH, Wnzel K, Suppan K, et al. Sleep attacks facts and fiction: A critical review. Adv Neurol 2003;91:335-41.
28. Sharf B, Moskovitz C, Lupton MD, et al. Dream phenomena induced by chronic levodopa therapy. J Neural Transm 1978;43:143-51.
29. Dobkin RD, Menza M, Bienfait KL, et al. Depression in Parkinson's disease: Symptom improvement and residual symptoms after acute pharmacologic management. Am J Geriatr Psychiatry 2011;19:222-9.
30. Menza M, Marin H, Kaufman K, et al. Citalopram treatment of depression in Parkinson's disease: The impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004;16:315-9.
31. Menza M, Dobkin RD, Marin H, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov Disord 2009; 24:1325-32.
32. Miguelez C, Grandoso L, Ugedo L. Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson's disease. Int J Neuropsychopharmacol 2011;14:187-200.
33. Pålhagen S, Qi H, Mårtensson B, et al. Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J Neurol 2010;257:524-32.
34. Menza M, Dobkin RD, Marin H, et al A. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-92.
35. Chung YC, Kim SR, Jin BK. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010;185: 1230-7.
36. Chung YC, Kim SR, Park JY, et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011;60: 963-74.
37. Kuan WL, Zhao JW, Barker RA. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology (Berl) 2008; 197:279-93.
38. Durif F, Vidailhet M, Bonnet AM, et al. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995;45:1855-8.
39. Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: Evidence from an open-label, prospective study. Clin Neuropharmacol 2001;24:221-7.
40. Han YS, Lee CS. Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells. Eur J Pharmacol 2009;604:36-44.
41. Steur EN. Increase of Parkinson disability after fluoxetine medication. Neurology 1993;43:211-3.
42. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992;53:278-82.
43. Montastruc JL, Pelat M, Verwaerde P, et al. Fluoxetine in orthostatic hypotension of Parkinson's disease: A clinical and experimental pilot study. Fundam Clin Pharmacol 1998;12:398-402.
44. Ceravolo R, Nuri A, Piccinni A, et al. Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms. Neurology 2000;55:1216-8.
45. Tesei S, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson's disease: A prospective study. Mov Disord 2000;15:986-9.
46. Chung KA, Carlson NE, Nutt JG. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology 2005;64:1797-8.
47. Richard IH, McDermott MP, Kurlan R, et al. SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-36.
48. Freijzer PL, Brenninkmeijer JH. Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation. Ned Rijdschr Geneeskd 2002;146:574-5.
49. Hamada Y, Miyamoto K, Inatsugi Y, et al. A case of Parkinson's disease with neuroleptic malignant syndrome induced by paroxetine. Rinsho Shinkeigaku 2006;46: 575-8.
50. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997;12: 756-9.
51. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Motor changes during sertraline treatment in depressed patients with Parkinson's disease. Eur J Neurol 2008; 15:953-9.
52. Marino S, Sessa E, Di Lorenzo G, et al. Sertraline in the treatment of depressive disorders in patients with Parkinson's disease. Neurol Sci 2008;29:391-5.
53. Devos D, Dujardin K, Poirot I, et al. Comparison of desi - pra mine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebocontrolled study. Mov Disord 2008;23:850-7.
54. Rampello L, Chiechio S, Raffaele R, et al. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol 2002; 25:21-4.
55. Linazasoro G. Worsening of Parkinson's disease by citalopram. Parkinsonism Relat Disord 2000;6:111-3.
56. Rabey JM, Orlov E, Korczyn AD. Comparison of fluvoxamine versus amitriptyline for treatment of depression in Parkinson's disease. Neurology 1996;46:A374.
57. Rajapakse S, Abeynaike L, Wickramarathne T. Venla - faxine-associated serotonin syndrome causing severe rhabdomyolysis and acute renal failure in a patient with idiopathic Parkinson disease. J Clin Psychopharmacol 2010;30:620-2.
58. Djaldetti R, Yust-Katz S, Kolianov V, et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007;30:201-5.
59. Lemke MR. Effect of reboxetine on depression in Parkin - son's disease patients. J Clin Psychiatry 2002;63:300-4.
60. Pintor L, Baillès E, Valldeoriola F, et al. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. Gen Hosp Psychiatry 2006;28:59-64.
61. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 1984;34:1092-4.
62. Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion. Ned Tijdschr Geneeskd 2000;144:2157-9.
63. Gebhardt S, Röttgers H, Bäcker A, et al. Treatment of panic disorder with bupropion in a patient with Parkinson's disease. J Clin Pharm Ther 2008;33:575-7.
64. Załuska M, Dyduch A. Bupropion in the treatment of depression in Parkinson's disease. Int Psychogeriatr 2011;23:325-7.
65. Mastrosimone F, Coluci d'Amato C, De Angelis G, et al. Personal experience with a combination of drugs in subjects with dopa resistant Parkinson's disease. J Med 1980; 11:377-83.
66. Piccinin GL, Piccirilli M, Agostini L. La terapia del Parkinson con l'associazione L-dopa (più carbidopa) e trazodone. Cl Terap 1981;96:621-6.
67. Avila A, Cardona X, Martin-Baranera M, et al. Does nefazodone improve both depression and Parkinson's disease? A pilot randomized trial. J Clin Psychopharmacol 2003;23:509-13.
68. Lemke MR, Brecht HM, Koester J, et al. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005;17:214-20.
69. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study. J Neurol 2006;253:601-7.
70. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: A randomised, double-blind, placebocontrolled trial. Lancet Neurol 2010;9:573-80.
71. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depressive disorder. Depress Anxiety 2000;11:58-65
72. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: A placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60.
73. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: A national multicentre prospective randomized study. Eur J Neurol 2003;10:399-406.
74. Pinter MM, Helscher RJ. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993;5: 135-46.
75. Rabey JM, Treves TA, Neufeld MY, et al. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 1995;45:432-4.
76. Chacko RC, Hurley RA, Harper RG, et al. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1995;7:471-5.
77. Wagner ML, Defilippi JL, Menza MA, et al. Clozapine for the treatment of psychosis in Parkinson's disease: Chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996;8:276-80.
78. Ruggieri S, De Pandis MF, Bonamartini A, et al. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol 1997;20:204-9.
79. Widman LP, Burke WJ, Pfeiffer RF, et al. Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: Retrospective review. J Geriatr Psychiatry Neurol 1997;10:63-6.
80. Svetel MV, Sternic NM, Filipovic SR, et al. Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa. Srp Arh Celok Lek 1997; 125:203-6.
81. Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience. Mov Disord 1998; 13:377-82.
82. Bonuccelli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration. Neurology 1997;49:1587-90.
83. Factor SA, Friedman JH, Lannon MC, et al. Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001;16:135-9.
84. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-95.
85. Klein C, Gordon J, Pollak L, et al. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuro - pharmacol 2003;26:8-11.
86. Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 2004;19:831-3.
87. Factor SA, Brown D, Molho ES, et al. Clozapine: A 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994;44:544-6.
88. Jansen EN. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994;89:262-5.
89. Friedman JH, Koller WC, Lannon MC, et al. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997;48:1077-81.
90. Arevalo GJ, Gershanik OS. Modulatory effect of clozapine on levodopa response in Parkinson's disease: A preliminary study. Mov Disord 1993;8:349-54.
91. Bennett JP Jr, Landow ER, Dietrich S, et al. Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994;9:409-14.
92. Durif F, Debilly B, Galitsky M, et al. Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebocontrolled study. Neurology 2004;62:381-8.
93. Pierelli F, Adipietro A, Soldati G, et al. Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand 1998;97:295-9.
94. Durif F, Vidailhet M, Assal F, et al. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1997;48:658-62.
95. Linazasoro G, Martí Massó JF, Suárez JA. Nocturnal akathisia in Parkinson's disease: Treatment with clozapine. Mov Disord 1993;8:171-4.
96. Friedman JH. Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases. Mov Disord 1994;9:321-4.
97. Kumar A, Chadda RK, Kumar N, et al. Clozapine for the treatment of neurogenic bladder. Neurourol Urodyn 2007; 26:537-9.
98. Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999;14:484-7.
99. Targum SD, Abbott JL. Efficacy of quetiapine in Parkin - son's patients with psychosis. J Clin Psychopharmacol 2000;20:54-60.
100. Kohmoto J, Kihira T, Miwa H, et al. Effect of quetiapine fumarate on drug-induced psychosis in patients with Parkinson's disease. No To Shinkei 2002;54:489-92.
101. Reddy S, Factor SA, Molho ES, et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002;17: 676-81
102. Giménez-Roldán S, Navarro E, Mateo D. Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson's disease. Rev Neurol 2003;36:401-4.
103. Wijnen HH, van der Heijden FM, van Schendel FM, et al. Quetiapine in the elderly with parkinsonism and psychosis. Eur Psychiatry 2003;18:372-3.
104. Mancini F, Tassorelli C, Martignoni E, et al. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. Clin Neuropharmacol 2004;27:33-7.
105. Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004;19:29-35.
106. Klein C, Prokhorov T, Miniovich A, et al. Long-term followup (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol 2006; 29:215-9.
107. Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkin - son's disease psychosis. Clin Neuropharmacol 2006;29: 331-7.
108. Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004;27:153-6. Erratum in: Clin Neuropharmacol 2004t;27:256.
109. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkin son's disease. Mov Disord 2005;20:958-63.
110. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: A doubleblind labeled study of 3 months' duration. Mov Disord2007;22:313-8.
111. Sommer BR. Quetiapine-induced extrapyramidal side effects in patients with Parkinson's disease: Case report. J Geriatr Psychiatry Neurol 2001;14:99-100.
112. Prueter C, Habermeyer B, Norra C, et al. Akathisia as a side effect of antipsychotic treatment with quetiapine in a patient with Parkinson's disease. Mov Disord 2003;18: 712-3.
113. Fernandez HH, Trieschmann ME, Friedman JH. Treat - ment of psychosis in Parkinson's disease: Safety considerations. Drug Saf 2003;26:643-59.
114. Katzenschlager R, Manson AJ, Evans A, et al. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: A double blind cross over study. J Neurol Neurosurg Psychiatry 2004;75:295-7.
115. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000; 15:301-4.
116. Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000;12:364-9.
117. Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial. Mov Disord 2000;15:1230-7.
118. Monreal JA, Staner L. Mania, parkinson disease and risperidone. Case report. Actas Esp Psiquiatr 2001;29: 349-50.
119. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Cliin Psychiatry 1995;56:556-9.
120. Wolters EC, Jansen EN, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-7.
121. Aarsland D, Larsen JP, Lim NG, et al. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999;11: 392-4.
122. Chacón JR, Durán E, Durán JA, et al. Usefulness of olanzapine in the levodopa-induced psychosis in patients with Parkinson's disease. Neurologia 2002;17:7-11.
123. Marsh L, Lyketsos C, Reich SG. Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. Psychosomatics 2001;42:477-81.
124. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-45.
125. Graham J, Sussman J, Ford K, et al. Olanzapine in the treatment of hallucinosis in idiopathic parkinson's disease: A cautionary note. J Neurol Neurosurg Psychiatry 1998;65:774-7.
126. Rudolf J, Ghaemi M, Schmülling S. Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine. Eur Psychiatry 1999; 14:356-7.
127. Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999;14: 1014-6.
128. Goetz CG, Blasucci LM, Leurgans S, et al. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:789-94.
129. Giménez-Roldán S, Mateo D, Navarro E, et al. Efficacy and safety of clozapine and olanzapine: An open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis. Parkinsonism Relat Disord 2001;7:121-7.
130. Durán-Ferreras E, Chacón-Peña JR, Durán-Quintana JA. The role of olanzapine in Parkinsonian dopaminergic psychosis. Rev Neurol 2002;35:691-6.
131. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-5.
132. Gómez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005;28:111-4.
133. López del Val LJ, Santos S. Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson's disease. Rev Neurol 2004;39:661-7.
134. Berkowitz AL. Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson's disease. Psychiatry (Edgmont) 2006;3:59-63.
135. Schindehütte J, Trenkwalder C. Treatment of druginduced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007;109:188-91.
136. Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: A diagnostic challenge. Hum Psychopharmacol 2004;19:205-7.
137. Oechsner M, Korchounov A. Parenteral ziprasidone: A new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? Hum Psychopharmacol 2005;20: 203-5.
138. Fernandez HH, Trieschmann ME, Friedman JH. Aripipra - zole for drug-induced psychosis in Parkinson disease: Preliminary experience. Clin Neuropharmacol 2004;27: 4-5.
139. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002;23:41-3.
140. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002;25: 107-10.
141. Kurita A, Ochiai Y, Kono Y, et al. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003;16: 184-8.
142. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-9.
143. Aarsland D, Laake K, Larsen J, et al. Donepezil for cognitive impairment in Parkinson's disease: A randomized controlled study. J Neurol Neurosurg Psychiatry 2002;72: 708-12.
144. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-907.
145. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord 2001;16:1171-4.
146. Rovers JM, Dautzenberg PL, ter Bruggen JP. Rivastig - mine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease. Tijdschr Gerontol Geriatr 2006;37:117-20.
147. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: A case series. Curr Med Res Opin 2002;18:258-64.
148. Veazey C, Cook KF, Stanley M, et al. Telephone-administered cognitive behavioral therapy: A case study of anxiety and depression in Parkinson's disease. J Clin Psychol Med Settings 2009;16:243-53.
149. Feeney F, Egan S, Gasson N. Treatment of depression and anxiety in Parkinson's disease: A pilot study using group cognitive behavioural therapy. Clin Psychol 2005;9:31-8.
150. Cole K, Vaughan FL. Brief cognitive-behavioral therapy for depression associated with Parkinson's disease: A single case series. Behav Cogn Psychother 2005;33:89-102.
151. Dobkin RD, Allen LA, Menza M. Cognitive behavior therapy for depression in Parkinson's disease: A pilot study. Mov Disord 2007;22:946-52.
152. Dreising H, Beckmann J, Wermuth L, et al. Psychologic effects of structured cognitive psychotherapy in young patients with Parkinson's disease: A pilot study. Nordic J Psychiatry 1999;53:217-21.
153. Farabaugh A, Locascio JJ, Yap L, et al. Cognitive-behavioral therapy for patients with Parkinson's disease and comorbid major depressive disorder. Psychosomatics 2010;51:124-9.
154. Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: A randomized, controlled trial. Am J Psychiatry 2011;168: 1066-74.
155. Fall PA, Ekman R, Granérus AK, et al. ECT in Parkinson's disease. Changes in motor symptoms, monoamine metabolites and neuropeptides. J Neural Transm Park Dis Dement Sect 1995;10:129-40.
156. Avila A, Sastre F, Cardona X, et al. Electroconvulsive therapy in Parkinson disease. Description of three cases. Neurologia 1997;12:313-6.
157. Weiner RD & Task Force on ECT. The practice of electroconvulsive therapy: Recommendations for treatment, training and privileging, second edition. Washington: American Psychiatric Association; 2001.
158. Ozer F, Meral H, Aydin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT 2005;21:125-7.
159. Bailine S, Kremen N, Kohen I, et al. Bitemporal electroconvulsive therapy for depression in a Parkinson disease patient with a deep-brain stimulator. J ECT 2008;24: 171-2.
160. Popeo D, Kellner CH. ECT for Parkinson's disease. Med Hypotheses 2009;73:468-9.
161. Nasr S, Murillo A, Katariwala N, et al. Case report of electroconvulsive therapy in a patient with Parkinson disease concomitant with deep brain stimulation. J ECT 2011; 27:89-90.
162. Höflich G, Burghof KW, Kasper S, et al. Electroconvulsive therapy in comorbidity of treatment refractory paranoid hallucinatory psychoses with Parkinson disease. Nervenarzt 1994;65:202-5.
163. Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 2010;26:111-5.
164. Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:1171-4.
165. Boggio PS, Fregni F, Bermpohl F, et al. Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression. Mov Disord 2005;20:1178-84.
166. Fregni F, Ono CR, Santos CM, et al. Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. Neurology 2006;66:1629-37.
167. Cardoso EF, Fregni F, Martins MF, et al. rTMS treatment for depression in Parkinson's disease increases BOLD responses in the left prefrontal cortex. Int J Neuropsycho - pharmacol 2008;11:173-83.
168. Fibiger HC, Phillips AG. Reward, motivation, cognition: Psychobiology of mesentelencephalic dopamine systems. In: Mountcastle VB, Bloom FE, Geiger SR, eds. Handbook of physiology. Vol 4: Intrinsic regulatory system of the brain. Section 1: The nervous system. Bethesda, MD: American Physiological Society; 1986: 647-76.
169. Sutoo D, Akiyama K. Music improves dopaminergic neurotransmission: Demonstration based on the effect of music on blood pressure regulation. Brain Res 2004;1016: 255-62.
170. Boso M, Politi P, Barale F, et al. Neurophysiology and neurobiology of the musical experience. Funct Neurol 2006;21: 187-91
171. Pacchetti C, Mancini F, Aglieri R, et al. Active music therapy in parkinson's disease: An integrative method for motor and emotional rehabilitation. Psychosom Med 2000; 62:386-93.
172. Nakamura R, Nagasaki H, Narabayashi H. Disturbances of rhythm formation in patients with Parkinson's disease. Percept Mot Skills 1978;46:63-75.
173. Sacks O. Awakenings. London: Pan Books; 1982.
174. Swallow M. Can music help people with Parkinson's disease? In: Koller WC, Paulson C, editors. Therapy of Parkinson's disease. New York: Marcel Dekker; 1990: 109-12.
175. Georgiou N, Iansek R, Bradshaw JL, et al. An evaluation of the role of internal cues in the pathogenesis of parkinsonian hypokinesia. Brain 1993;116:1578-87.
176. Thaut MH, McIntosh GC, Rice RR, et al. Rhythmic auditory stimulation in gait training for Parkinson's disease patients. Mov Disord 1996;2:193-200.
177. McIntosh GC, Brown SH, Rice RR, et al. Rhythmic auditory-motor facilitation of gait patterns in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62:22-6.
178. Magee WL, Davidson JW. The effect of music therapy onmood states in neurological patients: A pilot study. J Music Ther 2002;39:20-9.
179. Bernatzky G, Bernatzky P, Hesse HP, et al. Stimulating music increases motor coordination in patients afflicted with Morbus Parkinson. Neurosci Lett 2004;361:4-8
180. Schneider S, Schönle PW, Altenmüller E, et al. Using musical instruments to improve motor skill recovery following a stroke. J Neurol 2007;254:1339-46.
181. Schenck CH, Mahowald MW. Polysomnographic, neurologic, psychiatric, and clinical outcome report of 70 consecutive cases with the REM sleep behavior disorder (RBD): Sustained clonazepam efficacy in 89.5% of 57 treated patients. Clev Clin J Med 1990;57:10-24.
182. Garcia-Borreguero D, Larrosa O, Bravo M. Parkinson's disease and sleep. Sleep Med Rev 2003;7:115-29
183. Juri C, Chaná P, Tapia J, et al. Quetiapine for insomnia in Parkinson disease: Results from an open-label trial. Clin Neuropharmacol 2005;28:185-7.
184. Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: Results from a double-blind clinical-polysomnography study. Int J Neurosci 2009;119:2196-205.
185. Medeiros CA, Carvalhedo de Bruin PF, et al. Effect of exo - genous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebocontrolled study. J Neurol 2007;254:459-64.
186. Dowling GA, Mastick J, Colling E, et al. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med 2005;6:459-66.
187. Anton-Tay F, Diaz JL, Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci 1971;10:841-50.
188. Cotzias GC, Tang LC, Miller ST, et al. Melatonin and abnormal movements induced by l-DOPA in mice. Science 1971;173:450-2.
189. Papavasiliou PS, Cotzias GC, Duby SE, et al. Melatonin and parkinsonism. JAMA 1972;221:88-9.
190. Shaw KM, Stern GM, Sandler M. Melatonin and parkinsonism. Lancet 1973;1:271.
191. Willis GL, Armstrong SM. A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol Behav 1999;66:785-95.
192. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18: 287-93
193. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: Critique and recommendations. Mov Disord 2007;22:1077-92.
194. Dissanayaka NN, Sellbach A, Matheson S, et al. Validity of Hamilton Depression Inventory in Parkinson's disease. Mov Disord 2007;22:399-403.
195. Leentjens AF, Verhey FR, Lousberg R, et al. The validity of the Hamilton and Montgomery-Asberg Depression Rating Scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry 2000;15: 644-9.
196. Weintraub D, Oehlberg KA, Katz IR, et al. Test characteristics of the 15-Item Geriatric Depression Scale and Hamilton Depression Rating Scale in Parkinson disease. Am J Geriatr Psychiatry 2006;14:169-75.
197. Dissanayaka NN, O'Sullivan JD, Silburn PA, et al. Assessment methods and factors associated with depression in Parkinson's disease. J Neurol Sci 2011;310:208-10.
198. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1982;17:37-49.
199. Thompson AW, Liu H, Hays RD, et al. Diagnostic accuracy and agreement across three depression assessment measures for parkinson's disease. Parkinsonism Relat Disord 2011;17:40-5.
200. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13.
201. Leentjens AF, Dujardin K, Marsh L, et al. Anxiety rating scales in Parkinson's disease: Critique and recommendations. Mov Disord 2008;23:2015-25.
202. Diederich NJ, Goetz CG. The placebo treatment in neurosciences: New insights from clinical and neuroimaging studies. Neurology 2008;71:677-84
203. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder, third edition. Arlington, VA: American Psychiatric Association; 2010 (available at http:// psychiatryonline. org/content.aspx?bookid=28§ionid= 1667485, accessed February 28, 2013).
204. National Institute for Health and Clinical Excellence (NICE). Depression: The treatment and management of depression in adults. Clinical guideline 90. London: NICE; 2009 (available at www.nice.org.uk/nicemedia/pdf/ CG90NICEguideline.pdf, accessed February 28, 2013).
205. National Institute for Health and Clinical Excellence(NICE). Depression in adults with a chronic physical health problem. Clinical guideline 91. London: NICE; 2009 (available at www.nice.org.uk/nicemedia/live/12327/45909/45909.pdf, accessed February 28, 2013).
206. Wood LD, Neumiller JJ, Setter SM, et al. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. Am J Geriatr Pharmacother 2010;8: 294-315.
207. Preskorn SH. How and why study designs affect the nature and validity of study results: Appearance versus true knowledge. Part II. J Psychiatr Pract 2009;15:402-7.
208. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet 2009;373:746-58.
209. Labbate LA, Fava M, Rosenbaum JF, et al. Handbook of psychiatric drug therapy, 6th edition. Philadelphia: Lippincott Williams & Wilkins; 2010.
210. Balsara JJ, Jahdav SA, Gaonkar RK, et al. Effects of the antidepressant trazodone, a 5-HT2a/2c antagonist, on dopamine-dependent behavior in rats. Psychopharma - cology 2005;179:597-605.
211. Werneck AL, Rosso AL, Vincent MB. The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease. Arq Neuropsiquiatr 2009;67:407-12.
212. Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord 2005;20:104-5.
213. Touré JT, Brandt NJ, Limcangco MR, et al. Impact of second-generation antipsychotics on the use of antiparkinson agents in nursing homes and assisted-living facilities. Am J Geriatr Pharmacother 2006;4:25-35.
214. Miwa H, Morita S, Nakanishi I, et al. Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Parkinsonism Relat Disord 2004;10: 177-80.
215. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992;7:125-31.
216. Rustembegovic A, Sofic E, Wichart I. Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis. Med Arh 2006;60:211-2.
217. Factor SA, McAlarney T, Sanchez-Ramos JR, et al. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990;5:280-5.
218. Karlsen KH, Tanberg E, Arsland D, et al. Health related quality of life in Parkinson's disease: A prospective longitudinal study. J Neurol Neurosurg Psychiatry 2000;69: 584-9.
219. Fahn S, Elton RL, UPDRS program members. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, et al., eds. Recent developments in Parkinson's disease, volume 2. Florham Park, NJ: Macmillan Healthcare Information; 1987; 153-63.
220. Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998;13:895-9.
221. Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson's disease. A self-reported, community-based survey. Sleep Med. 2002;3:147-9.
222. Wang PS, Bohn RL, Glynn RJ, et al. Hazardous benzodiazepine regimens in the elderly: Effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001;158:892-8.
223. Hanlon JT, Horner RD, Schmader KE, et al. Benzo diaze - pine use and cognitive function among communitydwelling elderly. Clin Pharmacol Ther 1998;64:684-92.
224. Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: Comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003;26:261-82.
225. Weishaupt JH, Bartels C, Polking E, et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006;41:313-23.
226. Sainz RM, Mayo JC, Uria H, et al. The pineal neurohormone melatonin prevents in vivo and in vitro apoptosis in thymocytes. J Pineal Res 1995;19:178-88.
227. Dabbeni-Sala F, Di Santo S, Franceschini D, et al. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: A role for mitochondrial complex I activity. FASEB J 2001;15:164-70.
228. Zisapel N. Melatonin-dopamine interactions: From basic neurochemistry to a clinical setting. Cell Mol Neurobiol 2001;21:605-16.
229. Suzen S. Recent developments of melatonin related antioxidant compounds. Comb Chem High Throughput Screen 2006;9:409-19.
230. Ma J, Shaw VE, Mitrofanis J. Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkinsonism Relat Disord 2009;15:307-14.
231. Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther 2009;15: 345-57.
232. Adi N, Mash DC, Ali Y, et al. Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med Sci Monit 2010;16:BR61-7.
233. Morguenstern EA. Neuroendocrine and psychopharmacologic aspects of the pineal function. Melatonin and psychiatric disorders. Acta Psiquiatr Psicol Am Lat 1989;35: 71-9.
234. Sandyk R. Pineal melatonin and sensory symptoms in Parkinson disease. Ital J Neurol Sci 1989;10:399-403.
235. Vecchierini MF. [Sleep disturbances in Alzheimer's disease and other dementias]. Psychol Neuropsychiatr Vieil 2010;8:15-23.
236. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999;22:371-5.
237. Steven JP, Mendelson WB. The use of trazodone as a hypnotic: A critical review. J Clin Psychiatry 2004;65:752-5.
238. Rickels K, Morris RJ, Newman H, et al. Diphenhydramine in insomniac family practice patients: A double-blind study. J Clin Pharmacol 1983;23:234-42.
239. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: A randomized controlled trail. JAMA 1999;281:991-9.
240. Cicolin A, Lopiano L, Zibetti M, et al. Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients. Sleep Med 2004;5:207-10.